SMAD2 and Hepatic fibrosis: Galunisertib (LY2157299), an oral inhibitor of TGFβRI kinase, inhibited the phosphorylation of Smad2/3 in a liver fibrosis model, thereby suppressing the production and maturation of COL1A1 [21].